Armata Pharmaceuticals Files 8-K
Ticker: ARMP · Form: 8-K · Filed: Nov 12, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Armata Pharma dropped an 8-K, likely with financial updates and disclosures. Check it out.
AI Summary
Armata Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This 8-K filing indicates that Armata Pharmaceuticals has made a regulatory disclosure and submitted financial statements and exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and financial statements, without immediate indication of significant negative events.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- 5005 McConnell Avenue (address) — Principal executive offices
- Los Angeles, California (location) — Principal executive offices location
- 90066 (zip_code) — Principal executive offices zip code
FAQ
What specific information is being disclosed under Regulation FD?
The filing does not specify the exact nature of the Regulation FD disclosure, only that it is being reported.
What are the key financial statements and exhibits being filed?
The filing indicates that financial statements and exhibits are being submitted, but their specific content is not detailed in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 12, 2024.
What is Armata Pharmaceuticals' principal executive office address?
The principal executive office is located at 5005 McConnell Avenue, Los Angeles, California, 90066.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 91-1549568.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-12 07:07:37
Filing Documents
- tm2428148d1_8k.htm (8-K) — 25KB
- tm2428148d1_ex99-1.htm (EX-99.1) — 14KB
- 0001104659-24-116327.txt ( ) — 212KB
- armp-20241112.xsd (EX-101.SCH) — 3KB
- armp-20241112_lab.xml (EX-101.LAB) — 33KB
- armp-20241112_pre.xml (EX-101.PRE) — 22KB
- tm2428148d1_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 12, 2024, Armata Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has achieved full enrollment of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K"). The information in this Item 7.01 and Exhibit 99.1 attached to this Form 8-K are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 12, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 12, 2024 Armata Pharmaceuticals, Inc. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer